TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Modern clinical trials such as the ECHELON-2 and ALCANZA trials for PTCL and CTCL respectively, used minimum of 10% of CD30 staining for eligibility (Kim et al., 2018; Jagadeesh et al., 2019).